Clinical Trial

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-18.
Status change: Not Yet Recruiting → Recruiting 2026-04-27
Trial Details
NCT Number NCT07249879
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators: Gracell Biotechnologies (Shanghai) Co., Ltd.
Conditions Relapsed/Refractory Small Cell Lung Cancer
Enrollment 55 participants
Start Date 2026-03-03
Primary Completion 2026-11-10 (estimated)
Study Completion 2028-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-01